← Open Payments lookup

NPI 1306836507: Open Payments

NPI 1306836507. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$657 in 41 payments from 6 companies in 2025. Trend: 2023 $366 · 2024 $869 · 2025 $657

Food & beverage: $657
CompanyPaymentsAmount
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)16$221
ABBVIE INC.12$158
Alkermes, Inc.6$124
Teva Pharmaceuticals USA, Inc.2$60
Neurocrine BioSciences, Inc.3$58
Janssen Pharmaceuticals, Inc2$36

Products named: CAPLYTA, VRAYLAR, ARISTADA, UZEDY, INGREZZA, INVEGA SUSTENNA.